Document Detail

Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.
MedLine Citation:
PMID:  21495928     Owner:  NLM     Status:  MEDLINE    
Survival of childhood acute lymphoblastic leukemia (ALL) is one of the greatest medical success stories of the last four decades. Unfortunately, childhood ALL survivors experience medical late effects that increase their risk of morbidity and premature death, often due to heart and vascular disease. Research has helped elucidate the mechanisms and trajectory of direct damage to the heart from treatment exposure, particularly to anthracyclines, and has also contributed knowledge on the influences of related chronic conditions, such as obesity and insulin resistance on heart health in these survivors. This article summarizes the key issues associated with early morbidity and mortality from cardiac-related disease in childhood ALL survivors and suggests directions for interventions to improve long-term outcomes.
Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Related Documents :
9388038 - Rate-independent effects of the new class iii antiarrhythmic agent ambasilide on transm...
17467978 - Genetic determinants of qt interval variation and sudden cardiac death.
4066228 - The use of programmed electrical stimulation to assess the fibrillatory propensity of i...
12422068 - The premenstrual period and exacerbations in multiple sclerosis.
15052248 - Q-wave regression after acute myocardial infarction assessed by tl-201 myocardial perfu...
10428298 - Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disea...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Expert review of hematology     Volume:  4     ISSN:  1747-4094     ISO Abbreviation:  Expert Rev Hematol     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-04-18     Completed Date:  2011-08-10     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  101485942     Medline TA:  Expert Rev Hematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  185-97     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antineoplastic / adverse effects*,  therapeutic use
Heart Diseases / etiology
Human Growth Hormone / deficiency,  metabolism
Metabolic Diseases / complications
Obesity / complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications,  mortality,  therapy*
Stem Cell Transplantation
Grant Support
CA021765/CA/NCI NIH HHS; P30 CA021765/CA/NCI NIH HHS; P30 CA021765-27/CA/NCI NIH HHS
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 12629-01-5/Human Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Unfavorable-risk cytogenetics in acute myeloid leukemia.
Next Document:  Salvage therapy for relapsed chronic lymphocytic leukemia.